Biogened Valuation
Is BGD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BGD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BGD (PLN22) is trading above our estimate of fair value (PLN12.14)
Significantly Below Fair Value: BGD is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BGD?
Key metric: As BGD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BGD's PE Ratio? | |
|---|---|
| PE Ratio | 11.1x |
| Earnings | zł4.87m |
| Market Cap | zł54.04m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 6.1x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does BGD's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 35.5x | ||
CLN Celon Pharma | 77.4x | 14.4% | zł1.4b |
GEN Genomed Spólka Akcyjna | 39.2x | n/a | zł34.4m |
MAB Mabion | 19x | -116.7% | zł194.6m |
ADCI Arab Drug | 6.4x | n/a | ج.م619.3m |
BGD Biogened | 11.1x | n/a | zł54.0m |
Price-To-Earnings vs Peers: BGD is good value based on its Price-To-Earnings Ratio (11.1x) compared to the peer average (35.5x).
Price to Earnings Ratio vs Industry
How does BGD's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BGD is good value based on its Price-To-Earnings Ratio (11.1x) compared to the European Pharmaceuticals industry average (20.3x).
Price to Earnings Ratio vs Fair Ratio
What is BGD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 11.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BGD's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.